Skip to main content
Premium Trial:

Request an Annual Quote

NanoString Prices IPO at $10 per Share

NEW YORK (GenomeWeb News) – NanoString Technologies late on Tuesday priced its planned initial public offering at $10 per share.

The company expects to offer 5.4 million shares of its common stock in the offering. In a prospectus filed today, NanoString said that it anticipates net proceeds from the offering of about $50.2 million.

Additionally, it has granted the underwriters a 30-day option to purchase up to 810,000 shares to cover any over-allotments.

JP Morgan and Morgan Stanley are the book-running managers, while Leerink Swann and RW Baird are co-managers. NanoString plans to trade on the Nasdaq Global Market under ticker symbol "NSTG".

Seattle-based NanoString announced its plans to go public a month ago with a proposed maximum aggregate offering price of about $86.3 million. Two weeks ago, it said that the share price on the offering was expected to be between $13 and $15, which would have brought in as much as $77.6 million.

The firm said that it would use proceeds from the offering to commercialize its Prosigna Breast Cancer Assay after receiving US regulatory authorization, including the creation of a dedicated oncology sales force; support and grow the installed base of its nCounter molecular analysis systems among life science research customers; and develop new life sciences applications, chemistry, and instrumentation for the nCounter platform.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.